Expanding Treatment Options: Ceftobiprole Against Multidrug-Resistant Infections
DOI:
https://doi.org/10.63501/ntga6364Keywords:
Ceftobiprole, Antimicrobial resistance, Multidrug-resistant pathogensReferences
1. Murray CJ, Ikuta KS, Sharara F, Swetschinski L, Aguilar GR, Gray A, Han C, Bisignano C, Rao P, Wool E, Johnson SC. Global burden of bacterial antimicrobial resistance in 2019: a systematic analysis. The lancet. 2022 Feb 12;399(10325):629-55. https://pubmed.ncbi.nlm.nih.gov/35065702/
2. Meštrović T, Haller S, Robles Aguilar G, Meinen A, Gershberg Hayoon A, Geffers C, Dörre A, Abu Sin M, Gray AP, Swetschinski LR, Ikuta KS. Antimicrobial resistance burden landscape in Germany in 2019: a comparative country-level estimation. JAC-Antimicrobial Resistance. 2025 Aug;7(4):dlaf142. https://pubmed.ncbi.nlm.nih.gov/40823668/
3. US Food and Drug Administration. FDA approves new antibiotic for three different uses [Internet]. 2024 https://www.fda.gov/news-events/press-announcements/fda-approves-new-antibiotic-three-different-uses
4. El Solh AA. Ceftobiprole: a new broad spectrum cephalosporin. Expert opinion on pharmacotherapy. 2009 Jul 1;10(10):1675-86. https://pubmed.ncbi.nlm.nih.gov/19527192/